SCHEDULE DETAILS Event Schedules

 
  • 13 : 00 – 13 : 45

    Registration onsite and Lunch

  • 13 : 45 – 13 : 50

    Session Opening and Introduction

  • Breast Cancer Session

  • 13 : 50 – 14 : 00

    Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

  • GU Cancer Session

  • 09 : 30 – 09 : 35

    Welcome Day2 Session Opening and Introduction

  • 09 : 35 – 09 : 45

    Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk

  • 09 : 45 – 09 : 55

    Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.

More Details